MHRA (UK)
OTHER
Class 2 Medicines Recall: Xeal Pharma, Clopidogrel Oral Liquids (all strengths), EL(26)A/43
Published: 10/26/2026Detected: 10/26/2026
Summary preview
Initiates a Class 2 medicines recall related to Xeal Pharma clopidogrel oral suspension and oral solution products because testing indicates the finished products contain less clopidogrel than the label claim.
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accountcardiology
pediatrics
manufacturing
quality
safety
labeling
#MHRA
#recall
#Class 2
#clopidogrel
#oral suspension
Official Source Document Source Verified
Access the original document directly from MHRA.
More from MHRA (UK)
- Field Safety Notices: 5 to 9 October 202610/19/2026
- Field Safety Notices: 12 to 16 October 202610/19/2026
- Nova Biomedical StatStrip ketone test strips: risk of disruption to blood ketone testing due to quality-control failures and supply interruption DSI/2026/01310/16/2026
- Field Safety Notices: 27 to 31 January 202510/16/2026
- Continuous renal replacement therapy (CRRT): Consider delayed administration of concurrent echinocandins, such as caspofungin, to reduce the risk of adsorption onto new polyacrylonitrile (PAN)-based filter membranes DSI/2026/01410/13/2026